Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 2,978 | 12,772 | 29,111 | 2,279 | 1,401 |
| Gross Profit | 2,978 | 12,772 | 29,111 | 2,279 | 1,401 |
| Operating Expenses | 71,903 | 56,001 | 54,114 | 54,854 | 56,883 |
| Operating Income | -68,925 | -43,229 | -25,003 | -52,575 | -55,482 |
| Other Income | 29,398 | -48,948 | 8,355 | 13,568 | -38,285 |
| Pre-tax Income | -39,527 | -92,177 | -16,648 | -39,007 | -93,767 |
| Income Tax | N/A | N/A | -1 | N/A | N/A |
| Net Income Continuous | -39,527 | -92,177 | -16,647 | -39,007 | -93,767 |
| Net Income | $-39,527 | $-92,177 | $-16,647 | $-39,007 | $-93,767 |
| EPS Basic Total Ops | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 |
| EPS Basic Continuous Ops | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 |
| EPS Diluted Total Ops | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 |
| EPS Diluted Continuous Ops | -0.34 | -0.91 | -0.18 | -0.41 | -1.06 |
| EPS Diluted Before Non-Recurring Items | -0.49 | -0.95 | -0.18 | N/A | N/A |
| EBITDA(a) | $-68,873 | $-43,178 | $-24,975 | $-52,556 | $-55,467 |